Budesonide Formoterol PowerPoint Template

Formoterol and Budesonide PPT: Medical PowerPoint Template

• The Formoterol and Budesonide PowerPoint template is a dynamic medical PowerPoint presentation that will help you realize the full potential of your presentation.
• RxSlides slides, which include medical animations and infographics, will attract your audience, especially workers in pharmaceutical industries and medical students.
• You can rely on our demonstrated respiratory and pharmaceutical templates to provide a dynamic and appealing PowerPoint presentations to your audience.

Template Formoterol and Budesonide PowerPoint a dynamic and appealing PowerPoint presentation

Description and structure of the combination

• Formoterol and Budesonide Combination of:

1. An inhaled corticosteroid (ICS), budesonide
2. A long-acting beta-2 agonist (LABA), formoterol

• The chemical structures of both compounds are inserted in introductory slides.
• The combination is available in the market under the brand name Symbicort inhaler.

Indications

• It is indicated for the maintenance treatment of asthma in adult and pediatric patients, to better present asthma, you can download RxSlides's Asthma PowerPoint Template.
• Clinical trials also support this combination for reliever therapy, also used in adults for the maintenance treatment of chronic obstructive pulmonary disease COPD and to reduce exacerbation of the case.

Pharmacodynamics of the combination

Budesonide

• As a potent synthetic glucocorticosteroid with strong topical and weak systemic effects.
• Budesonide has a high local anti-inflammatory potency and it is rapidly bio-transformed in the liver.
• This favorable separation between topical anti-inflammatory activity and systemic effect is due to strong glucocorticosteroid receptor affinity and an effective first-pass metabolism with a short half-life.
• The anti-anaphylactic and anti-inflammatory effects of budesonide manifest as decreased bronchial obstruction in the early and late phase allergic reactions.
• When administered by inhalation at therapeutic doses, it has a direct, potent anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma without the adverse effects observed when corticosteroids are administered systemically.

Formoterol

• Formoterol is a potent, selective, fast and long-acting beta2-adrenergic stimulant used for the prevention and rapid relief of asthma and COPD symptoms.
• Formoterol produces relaxation of bronchial smooth muscle in patients with reversible airway obstruction.
• Formoterol provides dose-related benefits in pulmonary function and bronchoprotective effects.

Pharmacokinetics of the combination

Absorption

• Medical infographics in Formoterol and Budesonide PPT give comparative visuals explaining the absorption of the combination.
• For budesonide, the absorption rate was rapid and peak plasma concentration was reached in 20 minutes.
• Inhaled formoterol is rapidly absorbed and the maximum plasma concentration is reached within 10 minutes after inhalation.

Distribution

• The medical illustration shows that plasma protein binding is approximately 50% for formoterol and 90% for budesonide.
• The volume of distribution is about 4 L/kg for formoterol and 3 L/kg for budesonide.

Metabolism

• Formoterol and Budesonide PPT graphs show that Formoterol is inactivated via conjugation reactions (active O-demethylated and reformulated metabolites are formed, but they are seen mainly as inactivated conjugates).
• Budesonide undergoes extensive biotransformation in the liver (≈90%) into metabolites with low glucocorticosteroid activity.
• There are no indications of any metabolic interactions or displacement reactions between formoterol and budesonide.

Excretion (elimination)

• A significant part of a dose of formoterol is eliminated via hepatic metabolism followed by renal excretion.
• After inhalation of formoterol via turbuhaler, 8-13% of the delivered dose of formoterol is excreted unmetabolized in the urine.
• Formoterol has a high systemic clearance (approximately 1.4 L/min) and the late elimination half-life averages 17 hours.
• Budesonide is eliminated via metabolism, mainly catalyzed by the enzyme CYP3A4. The metabolites of budesonide are excreted in urine as such or in conjugated form.
• Only negligible amounts of unchanged budesonide have been detected in the urine.
• Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. Dosing averages 4 hours.
• variety of excretion (elimination) PowerPoint templates designed by RxSlides team can help you present this section in different way.

Contraindications

• Formoterol and Budesonide combination is contraindicated for people having sensitivity for any of the combination components and in status asthmaticus and people with cardiovascular comorbidities or heart diseases.

Precautions

• Medical icons and illustrations explain the side effects and precautions of a combination of Formoterol and Budesonide PPT templates.
• Side effects include palpitations, headache and cough.
• patients who have been taking inhaled beta2-agonists regularly should be instructed to discontinue the regular use of these drugs.
• Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.
• Patients should be informed not to exceed the prescribed dose of the combination.

Mechanism of action

The animated mechanism explaining asthma pathogenesis

• Mediators involved in the pathogenesis of asthma are described in Formoterol and Budesonide PPT, including histamine, leukotrienes, eosinophil chemotactic factor of anaphylaxis (ECF-A), neutrophil chemotactic factor (NCF), cytokines and several inflammatory mediators.
• Different cell types release these mediators, including airway epithelium, eosinophils, basophils, lung parenchyma, lymphocytes, macrophages, mast cells, neutrophils and platelets.

Illustrated mechanism of action of formoterol

• It is a relatively selective long-acting agonist of beta2-adrenergic receptors, although it does carry some degree of activity at beta1 and beta3 receptors.
• For beta2 receptor selectivity, it is desirable in treating pulmonary diseases such as COPD and asthma.
• Formoterol has demonstrated an approximately 200-fold greater activity at beta2 receptors over beta1 receptors.
• Formoterol stimulates intracellular adenylyl cyclase, an enzyme that converts ATP to cyclic AMP (cAMP).
• Animated illustrations in Formoterol and Budesonide PPT demonstrate increased levels of cAMP in bronchial smooth muscle tissue, resulting in the relaxation of these muscles and subsequent dilation of the airways, as well as inhibition of the release of hypersensitivity mediators (e.g., histamine, leukotrienes) from culprit cells, especially mast cells.

Illustrated mechanism of action of budesonide

• Formoterol and Budesonide PPT describe the combination mechanism in treating asthma.
• Orally inhaled corticosteroids reduce the immediate and late-phase allergic responses associated with allergies and chronic bronchial asthma.
• Corticosteroids inhibit the release of these mediators and inhibit Ige synthesis, attenuate mucous secretion and eicosanoid generation, up-regulate beta-receptors, promote vasoconstriction and suppress inflammatory cell influx and inflammatory processes.
• Clinical effects include reducing bronchial hyperresponsiveness to allergens, fewer asthma exacerbations and improved FEV1, peak-flow rate and respiratory symptoms.

How do you use the formoterol and budesonide combination turbohaler?

• Dynamic slides in Formoterol and Budesonide PPT explain how to use the combination turbo haler.

1. The first step is to hold the turbohaler upright and remove the cap.
2. The second step is to load the dose by twisting the base anticlockwise and back in the other direction until you hear a click.
3. The third step is to breathe out, away from the turbohaler.
4. The fourth step is to place the mouthpiece in your mouth and form a seal with your lips. Breathe deeply, Remove the turbohaler and hold your breath for up to 10 seconds.
5. The fifth step is to replace the cap and twist it until it’s appropriately on.

• These dynamic slides are valuable for community pharmacists, nurses and patient education purposes.

Comparative charts and infographics

• These slides in Formoterol and Budesonide PPT are comparison template slides between two or two pharmaceutical companies.
• The combination is available in the market under Symbicort (160/4.5 mcg or 80/4.5 mcg).

1. Inhaled twice daily.
2. Used for 12 years of age and older.

• Another famous drug available in the market is Foracort 200 Rotacap (200/6 mcg).
• You can compare using slides in this section according to brands and generics in your market.
• This section is of particular value for marketing managers, medical representatives and workers in the pharmaceutical field to explore their products of interest with visuals.

Medical infographics for case study

• The case study template of this Formoterol and Budesonide PPT presentation template will contain patient history, discussion, diagnosis, treatment and follow-up.

RxSlides visuals of formoterol and budesonide PowerPoint template

• This is a set of PowerPoint icons and illustrations related to budesonide and formoterol, which will help you customize the content of this 100% editable presentation according to your content and audience interest.